Castration-Sensitive Prostate Carcinoma

Oncology·MeSH: Prostatic Neoplasms

12 drugs in development·1 company·3 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
Apalutamide 60 mg or 240 mg tablets	KYNTRA BIO INC. (KYNB)
degarelix	KYNTRA BIO INC. (KYNB)
goserelin	KYNTRA BIO INC. (KYNB)
Leuprolide	KYNTRA BIO INC. (KYNB)
Vudalimab	KYNTRA BIO INC. (KYNB)

Phase 2(3)

Drug	Company
Histrelin	KYNTRA BIO INC. (KYNB)
Relugolix	KYNTRA BIO INC. (KYNB)
triptorelin	KYNTRA BIO INC. (KYNB)

Phase 4(4)

Drug	Company
Abiraterone	KYNTRA BIO INC. (KYNB)
Abiraterone acetate 250 mg or 500 mg tablets	KYNTRA BIO INC. (KYNB)
Apalutamide	KYNTRA BIO INC. (KYNB)
Darolutamide	KYNTRA BIO INC. (KYNB)

Compare drugs

Apalutamide 60 mg or 240 mg tablets vs degarelix Apalutamide 60 mg or 240 mg tablets vs goserelin Apalutamide 60 mg or 240 mg tablets vs Leuprolide

Frequently asked questions

How many drugs are in development for Castration-Sensitive Prostate Carcinoma?

BioSniper tracks 12 drugs in development for Castration-Sensitive Prostate Carcinoma across 1 company.

How many clinical trials target Castration-Sensitive Prostate Carcinoma?

There are 3 clinical trials targeting Castration-Sensitive Prostate Carcinoma tracked by BioSniper.

Deep-dive into Castration-Sensitive Prostate Carcinoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Castration-Sensitive Prostate Carcinoma — Drugs in Development & Clinical Trials | BioSniper